<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511846</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0763</org_study_id>
    <nct_id>NCT03511846</nct_id>
  </id_info>
  <brief_title>Pain Biomarker Study</brief_title>
  <acronym>PBS</acronym>
  <official_title>The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates molecular and physical biomarkers of headaches in order to better
      understand mechanisms of these diseases.

      There are 3 main parts:

        1. Use of capsaicin (active ingredient in hot chili peppers) to trigger release of
           calcitonin gene related peptide - the hypothesis is that this will be different in
           headache subjects compared to controls (and if so might be used to predict how these
           patients will respond to certain medications that modulate calcitonin gene-related
           peptide). Subjects will be given capsaicin as a cream applied to the forehead or the
           inner nostril, or a hot sauce that is ingested.

        2. Use of capsaicin to trigger eye watering - the hypothesis is that oxygen gas will slow
           down the amount of eye watering. Cluster headache patients respond very powerfully to
           oxygen gas but to very little else. The mechanism for oxygen is unknown but in rodents
           there is data that it works on the parasympathetic / lacrimal gland system. This study
           translates rodent data into humans in a non-invasive way to confirm the mechanism of
           this very effective treatment.

        3. Use of ice water to trigger headaches - brain freeze causes a very short-lived but
           intense headache that may cause similar biomarker release as other headache disorders.
           This may be a useful human model for other headache disorders.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 21, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>In the oxygen portion of the study, subjects and the outcomes assessors will be told that they will be receiving either medical air or oxygen.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Activation of trigeminoautonomic reflex as assessed by change in Calcitonin gene-related peptide (CGRP) levels from before stimulation to after stimulation.</measure>
    <time_frame>10 minutes before pain stimulation and 10 minutes, 20 minutes, 30 minutes, 60 minutes, and 90 minutes after pain stimulation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activation of trigeminoautonomic reflex as assessed by tear fluid production</measure>
    <time_frame>90 minutes after pain stimulation</time_frame>
    <description>The amount of tear fluid after each intervention will be measured via Schirmer strips</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation of trigeminoautonomic reflex as assessed by change in pituitary adenylate cyclase activating polypeptide-38 (PACAP-38) levels levels from before stimulation to after stimulation.</measure>
    <time_frame>10 minutes before pain stimulation and 10 minutes, 20 minutes, 30 minutes, 60 minutes, and 90 minutes after pain stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of trigeminoautonomic reflex as assessed by saliva production</measure>
    <time_frame>90 minutes after pain stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of trigeminoautonomic reflex as assessed by nasal fluid production</measure>
    <time_frame>90 minutes after pain stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of trigeminoautonomic reflex as assessed by tactile threshold measurement with von Frey Filaments</measure>
    <time_frame>90 minutes after pain stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of trigeminoautonomic reflex as assessed by dermal blood flow</measure>
    <time_frame>90 minutes after pain stimulation</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">371</enrollment>
  <condition>Migraine</condition>
  <condition>Cluster Headache</condition>
  <condition>Trigeminal Autonomic Cephalgia</condition>
  <condition>Hemicrania Continua</condition>
  <condition>Paroxysmal Hemicrania</condition>
  <condition>SUNCT</condition>
  <condition>Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing</condition>
  <arm_group>
    <arm_group_label>Oral capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral capsaicin and Medical Air</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral capsaicin and High Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical capsaicin and Medical Air</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical capsaicin and High Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal capsaicin and Medical Air</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal capsaicin and High Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold water irrigation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold water irrigation and Medical Air</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold water irrigation and Low Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold water irrigation and High Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral capsaicin</intervention_name>
    <description>Subjects will drink a solution with capsaicin</description>
    <arm_group_label>Oral capsaicin</arm_group_label>
    <arm_group_label>Oral capsaicin and Medical Air</arm_group_label>
    <arm_group_label>Oral Capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_label>Oral capsaicin and High Flow Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical capsaicin</intervention_name>
    <description>Capsaicin cream will be applied to the skin of the forehead, cheek, or leg</description>
    <arm_group_label>Topical capsaicin</arm_group_label>
    <arm_group_label>Topical capsaicin and Medical Air</arm_group_label>
    <arm_group_label>Topical capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_label>Topical capsaicin and High Flow Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal capsaicin</intervention_name>
    <description>Capsaicin cream will be applied to the nostril</description>
    <arm_group_label>Intranasal capsaicin</arm_group_label>
    <arm_group_label>Intranasal capsaicin and Medical Air</arm_group_label>
    <arm_group_label>Intranasal capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_label>Intranasal capsaicin and High Flow Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold Water Irrigation</intervention_name>
    <description>Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)</description>
    <arm_group_label>Cold water irrigation</arm_group_label>
    <arm_group_label>Cold water irrigation and Medical Air</arm_group_label>
    <arm_group_label>Cold water irrigation and Low Flow Oxygen</arm_group_label>
    <arm_group_label>Cold water irrigation and High Flow Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Air</intervention_name>
    <description>Subjects will be exposed to medical air</description>
    <arm_group_label>Oral capsaicin and Medical Air</arm_group_label>
    <arm_group_label>Topical capsaicin and Medical Air</arm_group_label>
    <arm_group_label>Intranasal capsaicin and Medical Air</arm_group_label>
    <arm_group_label>Cold water irrigation and Medical Air</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Flow Oxygen</intervention_name>
    <description>Subjects will be exposed to oxygen gas between 1-9 L/min</description>
    <arm_group_label>Oral Capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_label>Topical capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_label>Intranasal capsaicin and Low Flow Oxygen</arm_group_label>
    <arm_group_label>Cold water irrigation and Low Flow Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Flow Oxygen</intervention_name>
    <description>Subjects will be exposed to oxygen gas between 10-25 L/min</description>
    <arm_group_label>Oral capsaicin and High Flow Oxygen</arm_group_label>
    <arm_group_label>Topical capsaicin and High Flow Oxygen</arm_group_label>
    <arm_group_label>Intranasal capsaicin and High Flow Oxygen</arm_group_label>
    <arm_group_label>Cold water irrigation and High Flow Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of one of the following: a. Diagnosis of a primary headache disorder
             according to the International Headache Classification, including migraine with aura,
             migraine without aura, chronic migraine, tension headache, cluster headache,
             paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with
             conjunctival injection and tearing (SUNCT), short-lasting unilateral neuralgiform
             headache attacks with cranial autonomic symptoms (SUNA), and hemicrania continua; b.
             Diagnosed by a pain medicine physician with lumbar radiculopathy (possibly including
             neuropathic features, nerve impingement on MRI, or electromyography (EMG) report
             suggestive of lumbar radiculopathy); or c. Healthy control subject with no history of
             debilitating headaches or debilitating back pain / radiculopathy pain, and no
             headaches or back pain within the previous 3 months.

          -  Able to provide HIPAA authorization to share prior medical records/imaging

          -  Age 18 and older

        Exclusion Criteria:

          -  The following items exclude the subject from all portions of the study: a. Known
             history of cardiovascular or neurovascular diseases. These diseases may include
             carotid stenosis of &gt;50%, vertebral stenosis, peripheral vascular disease, angina or
             myocardial infarction, stroke, or vascular malformations; b. History of brain tumors
             or epilepsy; c. Active pregnancy or lactation; d. Daily cigarette, tobacco or nicotine
             use; e. Life expectancy less than 1 year, co-existing disease or other characteristic
             that precludes appropriate diagnosis of headache or spine pain; f. Active drug /
             alcohol use or dependence that, in the opinion of the investigator, would interfere
             with adherence to study requirements; or g. Inability or unwillingness of subject to
             give informed consent (e.g., ward of the state)

          -  The following items exclude the subject only from the capsaicin portion of the study:
             a. Known allergy to capsaicin or hot peppers

          -  The following items exclude the subject only from the oxygen portion of the study: a.
             Pulmonary or other non-headache diseases that require the use of supplemental oxygen

          -  The following items exclude the subject only from the cold water irrigation (ice
             water) portion of the study: a. Trauma, fractures, or congenital abnormalities of the
             soft palate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Burish, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Mark J Burish</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Brain Freeze</keyword>
  <keyword>Capsaicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Anencephaly</mesh_term>
    <mesh_term>Paroxysmal Hemicrania</mesh_term>
    <mesh_term>Trigeminal Autonomic Cephalalgias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

